Latest & greatest articles for hypertension

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hypertension or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hypertension and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hypertension

101. Diabetes - type 2: What do I need to know about prescribing antihypertensive drugs?

Diabetes - type 2: What do I need to know about prescribing antihypertensive drugs? Antihypertensive drugs | Prescribing information | Diabetes - type 2 | CKS | NICE Search CKS… Menu Antihypertensive drugs Diabetes - type 2: What do I need to know about prescribing antihypertensive drugs? Last revised in September 2019 What do I need to know about prescribing antihypertensive drugs? For detailed information on prescribing angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II receptor

2019 NICE Clinical Knowledge Summaries

102. Chronic Hypertension in Pregnancy

membership dues are waived but there is a discounted annual subscription fee of $95 for access to publications such as the Green Journal, Practice Bulletins, and Committee Opinions. Individual subscriptions include print and online access. . Jump to: Figures & Tables Box 1 Box 3. Table 1. American College of Obstetricians and Gynecologists Definitions of Hypertensive Disorders Table 2. Common Oral Antihypertensive Agents in Pregnancy Table 3. Antihypertensive Agents Used for Urgent Blood Pressure Control (...) Chronic Hypertension in Pregnancy Chronic Hypertension in Pregnancy | ACOG Clinical Guidance Journals & Publications Patient Education Topics Featured Clinical Topics Hi, Featured Clinical Topics Clinical Guidance Chronic Hypertension in Pregnancy Practice Bulletin Number 203 January 2019 Jump to Resources Share By reading this page you agree to ACOG's Terms and Conditions. and may result in significant maternal, fetal, and neonatal morbidity and mortality. The rate of maternal chronic

2019 American College of Obstetricians and Gynecologists

103. Gestational Hypertension and Preeclampsia

Gestational Hypertension and Preeclampsia Gestational Hypertension and Preeclampsia | ACOG Clinical Guidance Journals & Publications Patient Education Topics Featured Clinical Topics Hi, Featured Clinical Topics Clinical Guidance Gestational Hypertension and Preeclampsia Practice Bulletin Number 202 January 2019 Jump to Resources Share Nonmembers: Subscribe now to access exclusive ACOG Clinical content, including: ACOG Clinical is designed for easy and convenient access to the latest clinical

2019 American College of Obstetricians and Gynecologists

104. Effects of a health education intervention on hypertension-related knowledge, prevention and self-care practices in Nigerian retirees: a quasi-experimental study. Full Text available with Trip Pro

Effects of a health education intervention on hypertension-related knowledge, prevention and self-care practices in Nigerian retirees: a quasi-experimental study. Education is vital to increasing knowledge, improving prevention and self-care practices for hypertension in older adults. This study aimed to determine the effectiveness of a health education intervention in improving hypertension (HT) knowledge, prevention and self-care practices among retirees in Enugu State, South-east, Nigeria.In (...) ) included demographic variables, knowledge about hypertension, prevention and self-care practices. We used paired samples t-test, Chi-square test and one-way ANOVA repeated measures for data analyses.The mean age of the participants was 65.9 (± 8.9) years, the mean SBP and DBP were 136.5 (± 13.3) and 87.9 (± 9.1) respectively. More than half of the participants were (50.3%) were males, and the mean BMI was 23.9 (± 5.1) kg/m2. The paired comparison analysis showed that the mean HT knowledge score

2019 Archives of public health = Archives belges de sante publique Controlled trial quality: uncertain

105. Hypertension - not diabetic: Angiotensin-II receptor blockers

electrolytes 1–2 weeks after each upward titration. Monitor blood pressure 4 weeks after each dose titration. For more information, see . For people who are taking diuretics: If the person is taking a low-dose diuretic (for example bendroflumethiazide 2.5 mg daily), give a low starting dose of an ARB. Refer people who are taking high-dose diuretics (equivalent to 80 mg furosemide or more) to secondary care to initiate ARB treatment. Details of the usual starting, maintenance, and maximum doses of ARBs (...) of hyperkalaemia, hypotension, and renal impairment. People with diabetic neuropathy are particularly susceptible to developing hyperkalaemia and should not receive combination treatment. For people for whom combination therapy is considered essential, specialist supervision with close monitoring of blood pressure, renal function, and electrolytes is recommended - monitoring should be carried out when treatment commences, then monthly, and also after any change in dose or intercurrent illness. Diuretics

2019 NICE Clinical Knowledge Summaries

106. Hypertension - not diabetic: Angiotensin-converting enzyme inhibitors

, or the diuretic discontinued at least 24 hours beforehand. If high-dose diuretic therapy cannot be stopped, close observation is recommended for at least 2 hours following the first dose of ACE inhibitor, or until the blood pressure has stabilised. Allopurinol — possible increased risk of leucopenia and hypersensitivity reactions, especially in people with renal impairment. Bee/wasp venom extracts — risk of severe anaphylaxis. Non-steroidal anti-inflammatory drugs — increased risk of renal impairment (...) concomitant angiotensin-II receptor blocker or aliskiren. With hypovolaemia. With hyponatraemia (plasma sodium level less than 130 mmol/L). With hypotension (systolic blood pressure below 90 mmHg). With unstable heart failure. Receiving high-dose vasodilator therapy. With known renovascular disease. [ ] Monitoring Measure renal function (serum creatinine and estimated glomerular filtration rate) and serum electrolytes before starting treatment. Check renal function and serum electrolytes 1–2 weeks after

2019 NICE Clinical Knowledge Summaries

107. Hypertension - not diabetic: Alpha-blockers

, subsequent doses can be taken in the morning. Reassess response to treatment after at least 4 weeks, unless it is necessary to reduce the blood pressure more urgently. [ ; ; ] © . (...) Hypertension - not diabetic: Alpha-blockers Alpha-blockers | Prescribing information | Hypertension - not diabetic | CKS | NICE Search CKS… Menu Alpha-blockers Hypertension - not diabetic: Alpha-blockers Last revised in July 2020 Alpha-blockers Which alpha-blocker is recommended? Once-daily doxazosin and terazosin are recommended alpha-blocker drug options. Prescribe non-proprietary drugs where these are appropriate and minimise cost. [ ; ] Contraindications and cautions Do not use alpha

2019 NICE Clinical Knowledge Summaries

108. Hypertension - not diabetic

Hypertension - not diabetic Hypertension - not diabetic | Topics A to Z | CKS | NICE Search CKS… Menu Hypertension - not diabetic Hypertension - not diabetic Last revised in July 2020 Hypertension is persistently raised arterial blood pressure (BP). It is one of several risk factors for diseases Diagnosis Management Prescribing information Background information Hypertension - not diabetic: Summary Hypertension is persistently raised arterial blood pressure. It increases the risk of a number (...) of conditions, including heart failure, coronary artery disease, stroke, chronic kidney disease, peripheral arterial disease, and vascular dementia. Primary hypertension (which occurs in about 90% of people) has no identifiable cause. Secondary hypertension (about 10% of people) has a known underlying cause, such as renal, endocrine, or vascular disorder, or the use of certain drugs. Hypertension should be suspected if clinic systolic blood pressure is sustained above or equal to 140 mmHg, or diastolic

2019 NICE Clinical Knowledge Summaries

109. Adult nursing: Tai Chi: a promising adjunct nursing intervention to reduce risks of cardiovascular disease and improve psychosocial well-being in adults with hypertension

Adult nursing: Tai Chi: a promising adjunct nursing intervention to reduce risks of cardiovascular disease and improve psychosocial well-being in adults with hypertension Tai Chi: a promising adjunct nursing intervention to reduce risks of cardiovascular disease and improve psychosocial well-being in adults with hypertension | Evidence-Based Nursing Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Tai Chi: a promising adjunct nursing intervention to reduce risks of cardiovascular disease and improve psychosocial well-being in adults with hypertension Article Text Commentary Adult nursing Tai Chi: a promising adjunct nursing intervention to reduce risks

2019 Evidence-Based Nursing

110. Lack of effects of evidence-based, individualised counselling on medication use in insured patients with mild hypertension in China: a randomised controlled trial. Full Text available with Trip Pro

with mild primary hypertension, 10-year risk of cardiovascular diseases (CVDs) lower than 20% and no history of CVDs were recruited and randomly allocated to two groups. EBI plus general counselling was provided to the intervention group and general counselling alone to the control group. EBI counselling included information on the 10-year CVD risk and treatment benefit in terms of absolute risk reduction estimated for each individual and information on average side effects and costs of antihypertensive (...) Lack of effects of evidence-based, individualised counselling on medication use in insured patients with mild hypertension in China: a randomised controlled trial. To evaluate whether evidence-based, individualised (EBI) counselling regarding hypertension and the treatment would affect medication use in insured patients with mild hypertension in China.We conducted a parallel-group, randomised controlled trial in two primary care centres in Shenzhen, a metropolitan city in China. Patients

2019 BMJ evidence-based medicine Controlled trial quality: predicted high

111. Torsemide for Prevention of Persistent Postpartum Hypertension in Women With Preeclampsia: A Randomized Controlled Trial (Abstract)

, women were randomized one to one to oral torsemide, 20 mg/d, or placebo, for 5 days. Our primary outcome was blood pressure greater than or equal to 150 mm Hg systolic or 100 mm Hg diastolic (or both) on two occasions at least 4 hours apart by postpartum day 5 or by the time of hospital discharge. Assuming a 50% rate of persistent hypertension in women with preeclampsia, 118 participants were required to detect a 50% rate reduction. Analyses were by intention to treat.From August 2016 to September (...) Torsemide for Prevention of Persistent Postpartum Hypertension in Women With Preeclampsia: A Randomized Controlled Trial To evaluate whether torsemide reduces the rate of persistent postpartum hypertension in women with preeclampsia.We conducted a randomized, double-blind, placebo-controlled trial of women with preeclampsia at a tertiary center from August 2016 to September 2017. Those with gestational hypertension or renal or cardiopulmonary failure were excluded. Within 24 hours of delivery

2018 EvidenceUpdates

112. Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension (Abstract)

Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension The prognostic importance of follow-up haemodynamics and the validity of multidimensional risk assessment are not well established for systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH).We assessed incident SSc-PAH patients to determine the association between clinical and haemodynamic variables at baseline and first follow-up right heart catheterisation (RHC (...) ) with transplant-free survival. RHC variables included cardiac index, stroke volume index (SVI), pulmonary arterial compliance and pulmonary vascular resistance. Risk assessment was performed according to the number of low-risk criteria: functional class I or II, 6-min walking distance (6MWD) >440 m, right atrial pressure <8 mmHg and cardiac index ≥2.5 L·min-1·m-2Transplant-free survival from diagnosis (n=513) was 87%, 55% and 35% at 1, 3 and 5 years, respectively. At baseline, 6MWD was the only independent

2018 EvidenceUpdates

113. Distribution of diabetes, hypertension and non-communicable disease risk factors among adults in rural Bangladesh: a cross-sectional survey Full Text available with Trip Pro

or more risk factors compared with women in the most poor group (1.33 (95% CI 1.17 to 1.58)). The combined prevalence of impaired fasting glucose, impaired glucose tolerance and diabetes was 26.1% among men and 34.9% among women, and increased with age. The prevalence of prehypertension and hypertension was 30.7% and 15.9% among men and 27.2% and 22.5% among women, with similar rising prevalence with age.NCD risk factors, hyperglycaemia and raised blood pressure are an immediate health threat in rural (...) Distribution of diabetes, hypertension and non-communicable disease risk factors among adults in rural Bangladesh: a cross-sectional survey Non-communicable diseases (NCDs) are increasing in low-income settings. We conducted a survey of risk factors, blood pressure and blood glucose in rural Bangladesh and assessed variations by age, sex and wealth.We surveyed a random sample of 12 280 adults aged >30 years in 96 villages in rural Bangladesh. Fieldworkers measured blood glucose and conducted

2018 BMJ global health

114. Low plasma stem cell factor combined with high transforming growth factor-α identifies high-risk patients in pulmonary arterial hypertension Full Text available with Trip Pro

Low plasma stem cell factor combined with high transforming growth factor-α identifies high-risk patients in pulmonary arterial hypertension In pulmonary arterial hypertension (PAH), severe vasoconstriction and remodelling of small pulmonary arteries result in high mortality. Receptor tyrosine kinases and their ligands, such as transforming growth factor (TGF)-α, modulate proliferation in PAH. Although the receptor tyrosine kinase c-Kit has been shown to be overexpressed in PAH, the expression (...) resistance (r=-0.66, p<0.0001), cardiac index (r=0.66, p<0.0001), venous oxygen saturation (r=0.47, p<0.0008), mean right atrial pressure (r=-0.44, p<0.002) and N-terminal pro-brain natriuretic protein (r=-0.39, p<0.006). SCF was lower in "high-risk" compared to "intermediate-risk" (p=0.0015) or "low-risk" (p=0.0009) PAH patients. SCF and TGF-α levels combined (SCF/TGF-α) resulted in 85.7% sensitivity and 81.5% specificity for detecting high-risk patients (p<0.0001). Finally, REVEAL (Registry to Evaluate

2018 ERJ open research

115. Effects of dietary nitrate supplementation, from beetroot juice, on blood pressure in hypertensive pregnant women: A randomised, double-blind, placebo-controlled feasibility trial. Full Text available with Trip Pro

Effects of dietary nitrate supplementation, from beetroot juice, on blood pressure in hypertensive pregnant women: A randomised, double-blind, placebo-controlled feasibility trial. Chronic hypertension in pregnancy is associated with significant adverse pregnancy outcomes, increasing the risk of pre-eclampsia, fetal growth restriction and preterm birth. Dietary nitrate, abundant in green leafy vegetables and beetroot, is reduced in vivo to nitrite and subsequently nitric oxide, and has been (...) demonstrated to lower blood pressure, improve vascular compliance and enhance blood flow in non-pregnant humans and animals. The primary aims of this study were to determine the acceptability and efficacy of dietary nitrate supplementation, in the form of beetroot juice, to lower blood pressure in hypertensive pregnant women. In this double-blind, placebo-controlled feasibility trial, 40 pregnant women received either daily nitrate supplementation (70 mL beetroot juice, n = 20) or placebo (70 mL nitrate

2018 Nitric oxide : biology and chemistry Controlled trial quality: predicted high

116. Dietary Approaches to Stop Hypertension Diet and Activity to Limit Gestational Weight: Maternal Offspring Metabolics Family Intervention Trial, a Technology Enhanced Randomized Trial (Abstract)

Dietary Approaches to Stop Hypertension Diet and Activity to Limit Gestational Weight: Maternal Offspring Metabolics Family Intervention Trial, a Technology Enhanced Randomized Trial Technology-enhanced antenatal diet and lifestyle intervention could prevent excess gestational weight gain and benefit mother and child.A randomized clinical trial.Overweight and obese ethnically diverse pregnant women in Chicago, Illinois, were enrolled between October 2012 and December 2015, with antenatal data (...) collection completed by July 2016. Analysis was completed June 2017.Participants were randomized when their fetus was gestational age 16 weeks to dietitian-led Dietary Approaches to Stop Hypertension diet and physical activity coaching that was received as three individual and six group counseling sessions by phone and webinar. A commercially available smartphone application was used for self-monitoring diet and physical activity. Telephone, text message prompts, and e-mail reminders encouraged adherence

2018 EvidenceUpdates

117. Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial (Abstract)

Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial To assess the effect of liraglutide on 24-hour ambulatory blood pressure and heart rate in patients with hypertension (pre- and stage 1 hypertension) and inadequately controlled Type 2 diabetes (glycated haemoglobin 7%-10% [53-86 mmol/mol]).Eligible patients for this investigator-initiated, parallel-group, randomized, double-blind trial were (...) on stable background antihyperglycaemic therapy excluding insulin, glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase-4 inhibitors. Participants were centrally randomized in a 1:1 ratio to daily liraglutide 0.6 mg, titrated to 1.2 mg after the first week, or placebo for 5 weeks. The primary outcome was change in 24-hour ambulatory systolic blood pressure (SBP), and secondary outcomes included change in ambulatory diastolic blood pressure (DBP) and heart rate. We also assessed renal

2018 EvidenceUpdates

118. Diagnosis, Evaluation, and Management of High Blood Pressure in Children and Adolescents Full Text available with Trip Pro

Diagnosis, Evaluation, and Management of High Blood Pressure in Children and Adolescents Systemic hypertension is a major cause of morbidity and mortality in adulthood. High blood pressure (HBP) and repeated measures of HBP, hypertension (HTN), begin in youth. Knowledge of how best to diagnose, manage, and treat systemic HTN in children and adolescents is important for primary and subspecialty care providers.To provide a technical summary of the methodology used to generate the 2017 "Clinical (...) action statements (KASs) and additional recommendations regarding the diagnosis, management, and treatment of HBP in youth were the product of a detailed systematic review of the literature. A content outline establishing the breadth and depth was followed by the generation of 4 patient, intervention, comparison, outcome, time questions. Key questions addressed: (1) diagnosis of systemic HTN, (2) recommended work-up of systemic HTN, (3) optimal blood pressure (BP) goals, and (4) impact of high BP

2018 EvidenceUpdates

119. Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial (Abstract)

Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial

2018 EvidenceUpdates

120. The Impact of Pulmonary Hypertension in Preterm Infants with Severe Bronchopulmonary Dysplasia through 1 Year Full Text available with Trip Pro

The Impact of Pulmonary Hypertension in Preterm Infants with Severe Bronchopulmonary Dysplasia through 1 Year To assess the effect of pulmonary hypertension on neonatal intensive care unit mortality and hospital readmission through 1 year of corrected age in a large multicenter cohort of infants with severe bronchopulmonary dysplasia.This was a multicenter, retrospective cohort study of 1677 infants born <32 weeks of gestation with severe bronchopulmonary dysplasia enrolled in the Children's (...) Hospital Neonatal Consortium with records linked to the Pediatric Health Information System.Pulmonary hypertension occurred in 370 out of 1677 (22%) infants. During the neonatal admission, pulmonary hypertension was associated with mortality (OR 3.15, 95% CI 2.10-4.73, P < .001), ventilator support at 36 weeks of postmenstrual age (60% vs 40%, P < .001), duration of ventilation (72 IQR 30-124 vs 41 IQR 17-74 days, P < .001), and higher respiratory severity score (3.6 IQR 0.4-7.0 vs 0.8 IQR 0.3-3.3, P

2018 EvidenceUpdates